A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities

OBJECTIVES: Increasing the ceftaroline fosamil dose beyond 600 mg every 12 h may provide additional benefit for patients with complicated skin and soft tissue infections (cSSTIs) with severe inflammation and/or reduced pathogen susceptibility. A Phase III multicentre, randomized trial evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dryden, Matthew, Zhang, Yingyuan, Wilson, David, Iaconis, Joseph P., Gonzalez, Jesus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181396/
https://www.ncbi.nlm.nih.gov/pubmed/27585969
http://dx.doi.org/10.1093/jac/dkw333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181396/
https://www.ncbi.nlm.nih.gov/pubmed/27585969
http://dx.doi.org/10.1093/jac/dkw333

Ejemplares similares